Apimeds Pharmaceuticals US (APUS) Non Operating Interest Expenses (2024 - 2026)

Apimeds Pharmaceuticals US (APUS) has reported Non Operating Interest Expenses for 3 consecutive years, with $3.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Non Operating Interest Expenses rose 13883.5% year-over-year to $3.2 million; the trailing twelve-month figure through Jun 2026 stood at $3.5 million (up 2572.9% YoY), and the FY2025 full-year result was $283011.0, up 140.41% from the prior year.
• Non Operating Interest Expenses rose to $3.2 million in Q2 2026 per APUS's latest filing, from $215624.0 in the prior quarter.
• Across five years, Non Operating Interest Expenses topped out at $3.2 million in Q2 2026 and bottomed at $6301.0 in Q3 2025.
• Historically, Non Operating Interest Expenses has averaged $402720.6 across 3 years, with a median of $32638.0 in 2024.
• The sharpest annual moves came in 2025 and 2026: Non Operating Interest Expenses plunged 80.69% in 2025, then soared 13883.5% in 2026.
• Over 3 years, Non Operating Interest Expenses stood at $36050.0 in 2024, then jumped by 498.12% to $215624.0 in 2025, then surged by 1395.08% to $3.2 million in 2026.
• According to Business Quant data, Non Operating Interest Expenses over the past three periods registered $3.2 million, $215624.0, and $6301.0 for Q2 2026, Q4 2025, and Q3 2025 respectively.